Ghaziabad Online

Urinary Tract Infection Treatment Market Hits 1,614.32 Mn in 2027 and to grow at a CAGR of 3.2%

 Breaking News
  • No posts were found

Urinary Tract Infection Treatment Market Hits 1,614.32 Mn in 2027 and to grow at a CAGR of 3.2%

March 19
15:26 2021
Urinary Tract Infection Treatment Market Hits 1,614.32 Mn in 2027 and to grow at a CAGR of 3.2%

Urinary Tract Infection Treatment Market
The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027.

According to our new market research study on “Urinary Tract Infection Treatment Market to 2027 – COVID-19 Impact and Global Analysis – by Drug Class, Indication, and Distribution Channel,” the market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent.

Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment.

Request for sample Report at: https://www.theinsightpartners.com/sample/TIPRE00005931/

Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market.

R&D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for generic Nitrofurantoin capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used to treat UTI caused by Staphylococcus aureus, enterococci, etc. Further, in February 2020, a France-based pharmaceutical company announced Exblifep, a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime. i.e., the fourth-generation cephalosporin, which achieved primary endpoints in a clinical trial for complicated UTIs.

Moreover, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io’s Dip UTI test kits in boots pharmacies throughout the UK. Additionally, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr to treat complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In July 2019, the US FDA approved Recarbrio drug to treat cUTI and complicated intra-abdominal infection in adults. In June 2018, Achaogen, Inc. received the US FDA approval for ZEMDRI to treat cUTIs in adults. In November 2018, Allergan, announced the launch of the FDA accepted supplemental drug AVYCAZ to treat cUTIs and complicated intra-abdominal infections patients between the age group of 3 months to 18 years. Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period.

The COVID-19 pandemic was first reported in December 2019 in Wuhan (China). The impacts of this outbreak are being felt across several markets in the world. The demand for urinary tract infection treatment solutions has reduced amid this global crisis due to a significant shift in the focus toward the management, treatment, and prevention of COVID-19.

The Report Segments Urinary Tract Infection Treatment Market as Follows:

ByDrug Class

• Penicillin and Combinations
• Quinolones
• Cephalosporin
• Aminoglycoside Antibiotics
• Sulphonamides
• Nutritional Supplements

By Indication

• Complicated Urinary Tract Infection
• Uncomplicated Urinary Tract Infection

By Distribution Channel

• Hospital Pharmacies
• Gynaecology and Urology Clinics
• Retail Pharmacies and Drug Store
• Online Drug Stores

Buy this Report Research @ https://www.theinsightpartners.com/buy/TIPRE00005931/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share